Stock Events

Stock Events

Korsana Biosciences 

$24.24
0
-$1.57-6.07% 17:46 Today

Statistics

Day High
24.65
Day Low
23
52W High
59.36
52W Low
7.19
Volume
22,324
Avg. Volume
7,012
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-170.11%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.07MRevenue
-3.53MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KRSA. It's not an investment recommendation.
NVIDIA
5
NVDA
Palantir Technologies
5
PLTR
Apple
4
AAPL
Tesla
4
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Axsome Therapeutics
AXSM
Mkt Cap10.83B
Axsome Therapeutics develops novel therapies for CNS disorders, overlapping with Cyclerion's focus.
Biogen
BIIB
Mkt Cap32.63B
Biogen has a broad portfolio in neurology and neurodegenerative diseases, competing in similar markets as Cyclerion.
Palatin Technologies
PTN
Mkt Cap22.6M
Palatin Technologies works on treatments for diseases with a focus on CNS, posing competition in the therapeutic space.
Alkermes
ALKS
Mkt Cap7.73B
Alkermes has a focus on CNS disorders, including treatments for depression and schizophrenia, competing with Cyclerion's interests.
AMGEN
AMGN
Mkt Cap236.38B
Amgen, with its broad focus, has ventured into CNS treatments, potentially competing with Cyclerion's pipeline.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie has a growing interest in neurology and CNS disorders, directly competing with Cyclerion's research and development focus.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly has a significant presence in neurology, including Alzheimer's disease, competing in the same therapeutic area as Cyclerion.
Novartis
NVS
Mkt Cap304.1B
Novartis has a diverse portfolio that includes treatments for CNS disorders, making it a competitor.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a long history in CNS and neurology, including Alzheimer's and depression, competing in the same space as Cyclerion.

About

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
Show more...
CEO
Regina Graul
Employees
1
Country
United States
ISIN
US23255M3034

Listings

NASDAQ
US
KRSA
BOATS
BOATS
CYCN.BOATS
XNAS
US
CYCN

0 Comments

Share your thoughts

FAQ

What is Korsana Biosciences stock price today?▼
The current price of KRSA is $24.24 USD — it has decreased by -6.07% in the past 24 hours. Watch Korsana Biosciences stock price performance more closely on the chart.
What is Korsana Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Korsana Biosciences stocks are traded under the ticker KRSA.
What is Korsana Biosciences revenue for the last year?▼
Korsana Biosciences revenue for the last year amounts to 2.07M USD.
What is Korsana Biosciences net income for the last year?▼
KRSA net income for the last year is -3.53M USD.
How many employees does Korsana Biosciences have?▼
As of September 10, 2026, the company has 1 employees.
In which sector is Korsana Biosciences located?▼
Korsana Biosciences operates in the Health & Wellness sector.
When did Korsana Biosciences complete a stock split?▼
Korsana Biosciences has not had any recent stock splits.
Where is Korsana Biosciences headquartered?▼
Korsana Biosciences is headquartered in CAMBRIDGE, United States.